Quarterly ResultJul 13, 2026, 04:27 PM
Lexaria Q3 Net Loss $1.99M; Zero Revenue; Going Concern Doubt
AI Summary
Lexaria Bioscience Corp. reported a net loss attributable to shareholders of $1.99 million for the three months ended May 31, 2026, with no revenue generated during the quarter. For the nine months ended May 31, 2026, the net loss was $5.04 million on $20,000 in revenue. The company raised $6.5 million from share sales but noted substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
Key Highlights
- Net loss attributable to shareholders for Q3 2026 was $1.99 million.
- Revenue for Q3 2026 was $0, down from $174,000 in Q3 2025.
- Basic and diluted loss per share for Q3 2026 was $(0.08).
- Cash balance as of May 31, 2026, was $3.48 million.
- Company raised $6.52 million from share sales in the nine months ended May 31, 2026.
- Accumulated deficit reached $68.5 million as of May 31, 2026.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
Price Impact
More from LEXX